259 related articles for article (PubMed ID: 18945310)
21. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature.
Zingarelli S; Frassi M; Bazzani C; Scarsi M; Puoti M; Airò P
J Rheumatol; 2009 Jun; 36(6):1188-94. PubMed ID: 19447932
[TBL] [Abstract][Full Text] [Related]
22. [Tuberculosis among patients treated with TNF-alpha blockers].
Fuchs-Polychuck I; Avnon LS; Abu-Shakra M
Harefuah; 2007 Mar; 146(3):212-8, 245. PubMed ID: 17460930
[TBL] [Abstract][Full Text] [Related]
23. Infection risk associated with anti-TNF-α agents: a review.
Murdaca G; Spanò F; Contatore M; Guastalla A; Penza E; Magnani O; Puppo F
Expert Opin Drug Saf; 2015 Apr; 14(4):571-82. PubMed ID: 25630559
[TBL] [Abstract][Full Text] [Related]
24. Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice.
Elewaut D; Matucci-Cerinic M
Rheumatology (Oxford); 2009 Sep; 48(9):1029-35. PubMed ID: 19561158
[TBL] [Abstract][Full Text] [Related]
25. [Infectious risks of immunomodulating therapies in rheumatology].
Van Delden C
Rev Med Suisse; 2006 Mar; 2(57):738-40, 743-5. PubMed ID: 16604876
[TBL] [Abstract][Full Text] [Related]
26. Targets of anticytokine therapy and the risk of infections in humans and mice.
van de Vosse E; van Agtmael MA
Curr Opin Rheumatol; 2007 Nov; 19(6):626-35. PubMed ID: 17917545
[TBL] [Abstract][Full Text] [Related]
27. Tumor necrosis factor-alpha antagonists and neuropathy.
Stübgen JP
Muscle Nerve; 2008 Mar; 37(3):281-92. PubMed ID: 18041052
[TBL] [Abstract][Full Text] [Related]
28. Tumour necrosis factor alpha as a therapeutic target for immune-mediated inflammatory diseases.
Taylor PC; Williams RO; Feldmann M
Curr Opin Biotechnol; 2004 Dec; 15(6):557-63. PubMed ID: 15560982
[TBL] [Abstract][Full Text] [Related]
29. Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis.
Channual J; Wu JJ; Dann FJ
Dermatol Ther; 2009; 22(1):61-73. PubMed ID: 19222518
[TBL] [Abstract][Full Text] [Related]
30. Tumor necrosis factor inhibition and invasive fungal infections.
Filler SG; Yeaman MR; Sheppard DC
Clin Infect Dis; 2005 Aug; 41 Suppl 3():S208-12. PubMed ID: 15983902
[TBL] [Abstract][Full Text] [Related]
31. Treatment of rheumatic diseases in patients with HCV and HIV infection.
Galeazzi M; Giannitti C; Manganelli S; Benucci M; Scarpato S; Bazzani C; Caporali R; Sebastiani GD
Autoimmun Rev; 2008 Dec; 8(2):100-3. PubMed ID: 18694850
[TBL] [Abstract][Full Text] [Related]
32. Tumor necrosis factor blockade and the risk of viral infection.
Kim SY; Solomon DH
Nat Rev Rheumatol; 2010 Mar; 6(3):165-74. PubMed ID: 20142812
[TBL] [Abstract][Full Text] [Related]
33. Mycobacterium mucogenicum: report of a skin infection associated with etanercept.
Shehan JM; Sarma DP
Dermatol Online J; 2008 Jan; 14(1):5. PubMed ID: 18319022
[TBL] [Abstract][Full Text] [Related]
34. Tuberculosis in patients treated with tumor necrosis factor-alpha antagonists living in an endemic area. Is the risk worthwhile?
Rojas-Villarraga A; Agudelo CA; Pineda-Tamayo R; Porras A; Matute G; Anaya JM
Biomedica; 2007 Jun; 27(2):159-71. PubMed ID: 17713627
[TBL] [Abstract][Full Text] [Related]
35. The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression?
Soczynska JK; Kennedy SH; Goldstein BI; Lachowski A; Woldeyohannes HO; McIntyre RS
Neurotoxicology; 2009 Jul; 30(4):497-521. PubMed ID: 19477018
[TBL] [Abstract][Full Text] [Related]
36. Antiviral therapy in patients with hematologic malignancies, transplantation, and aplastic anemia.
Jancel T; Penzak SR
Semin Hematol; 2009 Jul; 46(3):230-47. PubMed ID: 19549576
[TBL] [Abstract][Full Text] [Related]
37. Risks and benefits of the use of concomitant immunosuppressives and biologics in inflammatory bowel disease.
Shah SB; Hanauer SB
Rev Gastroenterol Disord; 2008; 8(3):159-68. PubMed ID: 18957923
[TBL] [Abstract][Full Text] [Related]
38. Primary varicella-zoster infection in patients on biologic therapies for psoriasis.
Hackett CB; Kirby B
Br J Dermatol; 2010 Nov; 163(5):1122. PubMed ID: 20633011
[No Abstract] [Full Text] [Related]
39. Management of moderate to severe plaque psoriasis (part I): clinical update on antitumor necrosis factor agents.
Sobell JM; Kalb RE; Weinberg JM
J Drugs Dermatol; 2009 Feb; 8(2):147-54. PubMed ID: 19213230
[TBL] [Abstract][Full Text] [Related]
40. Part XIV. Antiviral agents other than antiretrovirals: therapy for herpesvirus infections, viral hepatitis, and influenza.
Lockhart SM; Salvaggio MR; Bronze MS; Greenfield RA
J Okla State Med Assoc; 2007 Oct; 100(10):388-95. PubMed ID: 18085096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
